A Single Center, Open-label, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IM156 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 27 Dec 2018
At a glance
- Drugs IM 156 (Primary)
- Indications Glioblastoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors ImmunoMet Therapeutics
- 18 Dec 2018 Planned End Date changed from 1 Nov 2018 to 1 Aug 2019.
- 18 Dec 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Jun 2019.
- 05 Jun 2018 Trail design presented at the 54th Annual Meeting of the American Society of Clinical Oncology